First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

          First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcomaDecember 02, 2024 4:00 PM EST | Source: Adaptimmune Therapeutics PLCPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today  ...